Gillian Hirst

Assistant Professor

University of California, San Francisco

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (13)

Rebecca Shatsky

Associate Professor of Medicine

University of California San Diego School of Medicine

UNITED STATES

View details

James Korkola

Assistant Professor

Oregon Health & Science University

UNITED STATES

View details

W. Fraser Symmans

UNITED STATES

View details

Nusrat Jahan

Assistant Professor

The University of Alabama

UNITED STATES

View details

Julie E. Lang

University of Southern California

UNITED STATES

View details

Amit Kulkarni

University of Minnesota

UNITED STATES

View details

Douglas Yee

University of Minnesota

UNITED STATES

View details

Phoebe Miller

University of California, San Francisco

UNITED STATES

View details

Jacquelyn Roger

University of California, San Francisco

UNITED STATES

View details

Claudine Isaacs

Professor of Medicine

Georgetown University

UNITED STATES

View details

LAMORNA SWIGART

University of California, San Francisco

UNITED STATES

View details

Rita A. Mukhtar

University of California

UNITED STATES

View details

Rosalyn Sayaman

Assistant Adjunct Professor

University of California, San Francisco

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gillian Hirst

Research Interests

Explore related searches

Contact this professor

Articles (19)

Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.

Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer

Development and testing of a polygenic risk score for breast cancer aggressiveness

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.

Identifying Good Candidates for Active Surveillance of Ductal Carcinoma <i>In Situ</i>: Insights from a Large Neoadjuvant Endocrine Therapy Cohort

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.

The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.

Collaborators (13)

Rebecca Shatsky

James Korkola

W. Fraser Symmans

Nusrat Jahan

Julie E. Lang

Amit Kulkarni

Douglas Yee

Phoebe Miller

Jacquelyn Roger

Claudine Isaacs

LAMORNA SWIGART

Rita A. Mukhtar

Rosalyn Sayaman

Make your next move.